NATURA BISSE and ARCH AMENITIES GROUP EUROPE sign an agreement for the European Union and United Kingdom market

Natura Bissé and Arch Amenities Group Europe today announce a collaboration agreement with the aim of increasing their presence in the luxury spa sector throughout the European Union and the United Kingdom. The agreement will bring a great opportunity for additional…

Read MoreNATURA BISSE and ARCH AMENITIES GROUP EUROPE sign an agreement for the European Union and United Kingdom market

New EHR Integration Simplifies Provider Workflow for Patients Living With Diabetes

Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce the launch of its state-of-the-art Electronic Health Record (EHR) integration for its cutting-edge diabetes data visualization platform. This groundbreaking integration marks a significant advancement in the…

Read MoreNew EHR Integration Simplifies Provider Workflow for Patients Living With Diabetes

Sonendo, Inc. Announces Suspension of NYSE Trading, Will Commence Trading on the OTCQX Effective November 22, 2023

Sonendo, Inc. (NYSE: SONX) (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today announced that, on November 15, 2023, it received a notice from the New York Stock Exchange (the “NYSE”) that the…

Read MoreSonendo, Inc. Announces Suspension of NYSE Trading, Will Commence Trading on the OTCQX Effective November 22, 2023
Sensei

RootPath Announces Its Custom Gene Library, Slashing Gene Synthesis Cost by More Than Half

RootPath announced today the US launch of its flagship product, RootPath Custom Gene Library. Similar to conventional gene synthesis products, this product is delivered as individual, sequence-verified plasmids in 96- or 384-well plates. However, the cost is significantly lower. In…

Read MoreRootPath Announces Its Custom Gene Library, Slashing Gene Synthesis Cost by More Than Half

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

–Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will…

Read MoreIronwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

EVOLVE MVMT Launches First Wearable Optimizing Weight Loss Through Walking Form, Tracking Quality of Steps

EVOLVE MVMT, a first-of-its-kind wearable that aims to optimize human movement through walking, is the first to analyze not just quantity, but quality, of steps. EVOLVE MVMT enables users to enhance their walking technique to achieve significant health benefits like…

Read MoreEVOLVE MVMT Launches First Wearable Optimizing Weight Loss Through Walking Form, Tracking Quality of Steps

Genethon Announces Publication in The Lancet Neurology of Clinical Trial Results of a Gene Therapy for Myotubular Myopathy, a Severe Muscle Disease

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), today announced The Lancet Neurology published online preliminary results of a clinical trial conducted by Astellas Pharma using a gene therapy developed by Genethon for X-linked myotubular myopathy,…

Read MoreGenethon Announces Publication in The Lancet Neurology of Clinical Trial Results of a Gene Therapy for Myotubular Myopathy, a Severe Muscle Disease

University of Wisconsin–Madison and GE HealthCare Broaden Shared Commitment to Healthcare Innovation

The University of Wisconsin School of Medicine and Public Health at UW–Madison and GE HealthCare announced today a 10-year strategic collaboration that builds on an iconic relationship spanning more than 40 years. The new research collaboration ex Combining UW–Madison’s world-class…

Read MoreUniversity of Wisconsin–Madison and GE HealthCare Broaden Shared Commitment to Healthcare Innovation

Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients

Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment decisions for patients with metastatic or recurrent squamous cell carcinoma…

Read MoreCofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients